Tech Center 1600 • Art Units: 1656
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18389403 | METHODS FOR ASSAYING ENZYME ACTIVITY | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18976712 | NOVEL STRAINS AND METHODS FOR THE CONTINUOUS PRODUCTION OF A NUTRITIVE COMPOSITION | Final Rejection | LanzaTech, Inc. |
| 18165620 | METHOD OF PRODUCING HYDROGEN PEROXIDE USING MICROORGANISM OF THE GENUS DESEMZIA | Non-Final OA | Gwangju Institute of Science and Technology |
| 18391959 | ENGINEERED PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | Pairwise Plants Services, Inc. |
| 18577341 | MYCOREMEDIATION OF CONTAMINANTS | Final Rejection | MYCOCYCLE, INC. |
| 18266274 | PULSED ELECTRIC FIELD TREATMENT OF BIOLOGICAL CELLS | Non-Final OA | Bühler AG |
| 17777245 | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18478179 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | Non-Final OA | Prime Medicine, Inc. |
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | Non-Final OA | Numaferm GmbH |
| 17922407 | VACCINE COMPOSITION FOR PREVENTING OR TREATING INFECTION OF SARS-COV-2 | Non-Final OA | SK BIOSCIENCE CO., LTD. |
| 18278778 | METHOD FOR PRODUCING A PERIPLASMIC FORM OF THE PROTEIN CRM197 | Non-Final OA | CURAVAC EUROPE |
| 17774215 | METHODS FOR DISTINGUISHING THE STAGES OF BACTERIAL VAGINOSIS | Final Rejection | University Of Maryland, Baltimore |
| 18344501 | EVALUATION METHOD OF PATHOGEN INACTIVATION EFFECT | Non-Final OA | Institute of Blood Transfusion, CAMS |
| 17780336 | METHOD OF LYOPHILIZATION OF A CRYOGENIZED CELLULAR COMPOSITION CONTAINING DISSOLVED GAS | Final Rejection | LARENA |
| 17762988 | NANO-PERFORATOR HAVING IMPROVED ANTI-VIRAL ACTIVITY | Non-Final OA | MVRIX Co., Ltd. |
| 17608451 | Nanocellulose 3D Matrix for Cultivating Human and Animal Cells in Vitro | Final Rejection | BIOCELLTIS BIOTECNOLOGIA S/A |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy